{"id":4060,"date":"2019-02-07T12:10:16","date_gmt":"2019-02-07T06:40:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4060"},"modified":"2021-07-24T12:57:11","modified_gmt":"2021-07-24T07:27:11","slug":"the-business-cocktail-55","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55","title":{"rendered":"Genentech remunerates Xencor; XPrize upraises fund; GSK gambles"},"content":{"rendered":"\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Genentech remunerates Xencor USD 120 Million for global\nrights <\/strong><\/p>\n\n\n\n<p><strong>Genentech <\/strong>has&nbsp;remunerated&nbsp;<strong>USD 120 million<\/strong> upfront to have global rights to <strong>IL-15 cytokine therapeutics<\/strong> in preclinical development at <strong>Xencor<\/strong>. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural killer and <strong>cytotoxic <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/t-cell-inhibitor-pipeline-insight\"><strong>T cells<\/strong> <\/a>without activating the simultaneous temporary increase in regulatory T cell activity associated with the targeting of IL-2. This has intrigued <strong>Eli Lilly and Novartis.<\/strong> However, Xencor beliefs its technology can provide better tolerability and a longer half-life.&nbsp;<\/p>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>The board member of XPrize upraises USD 100 Million fund <\/strong><\/p>\n\n\n\n<p><strong>XPRIZE <\/strong>is a nonprofit organization that designs and manages public competitions intended to encourage technological development that could benefit humanity.&nbsp;It has plans to invest <strong>USD 100 million<\/strong> in startups for extending healthy lifespans. The fund will boost the capital into biotechs and other startups that are based across the globe for series B rounds.<\/p>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>GSK gambles billions more on oncology<\/strong><\/p>\n\n\n\n<p><strong>GlaxoSmithKline and Merck KGaA<\/strong> have come for a joint development and commercialization deal for investigational immuno-oncology drugs. <strong>M7824<\/strong> is a fusion protein that aims two immune system-suppressing pathways, including the <strong>PD-L1 pathway <\/strong>that produced drugs like Keytruda and Opdivo.&nbsp; The researchers have tested M7824 \u200bover 700 patients in the clinic and more than 10 tumor types. The drug is the furthest along in advanced non-small cell lung cancer, where a Phase 2 study is evaluating it against Keytruda in patients who express PD-L1. Merck KGaA is receiving USD 343 million upfront through the GSK agreement and could receive up to USD 3.9 billion in milestone payments.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Genentech remunerates Xencor USD 120 Million for global rights Genentech has&nbsp;remunerated&nbsp;USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural killer and cytotoxic T cells without activating the simultaneous temporary increase in regulatory T [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3458,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1135,903,2538,395,423],"industry":[17225],"therapeutic_areas":[17235,17228],"class_list":["post-4060","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-genentech","tag-gsk","tag-m7824","tag-merck","tag-novartis","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Genentech-Xencor $120M deal; XPrize upraises $100M; GSK-Merck&#039;s deal<\/title>\n<meta name=\"description\" content=\"Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genentech-Xencor $120M deal; XPrize upraises $100M; GSK-Merck&#039;s deal\" \/>\n<meta property=\"og:description\" content=\"Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-07T06:40:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"3000\" \/>\n\t<meta property=\"og:image:height\" content=\"1875\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genentech-Xencor $120M deal; XPrize upraises $100M; GSK-Merck's deal","description":"Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55","og_locale":"en_US","og_type":"article","og_title":"Genentech-Xencor $120M deal; XPrize upraises $100M; GSK-Merck's deal","og_description":"Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor.....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-02-07T06:40:16+00:00","article_modified_time":"2021-07-24T07:27:11+00:00","og_image":[{"width":3000,"height":1875,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55","name":"Genentech-Xencor $120M deal; XPrize upraises $100M; GSK-Merck's deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","datePublished":"2019-02-07T06:40:16+00:00","dateModified":"2021-07-24T07:27:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-55#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma.jpg","width":"3000","height":"1875","caption":"100 dollar bills, pills, and medicine containers"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022445\/636120797170066506-1197617263_badpharma-300x188.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genentech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">M7824<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Genentech<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">M7824<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 7, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 7, 2019 12:10 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"100 dollar bills, pills, and medicine containers","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4060"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4060\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3458"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4060"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4060"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}